Future directions of liposome- and immunoliposome-based cancer therapeutics

Seminars in Oncology

Volumn 31, Issue SUPPL. 13, 2004, Pages 196-205

  Park, John W ^a   Benz, Christopher C ^b   Martin, Francis J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAMPTOTHECIN; CETUXIMAB; DOXORUBICIN; IMMUNOLIPOSOME; IRINOTECAN; LIPOSOME; LURTOTECAN; METHOTREXATE; NANOPARTICLE; NAVELBINE; POLYMER; TOPOTECAN; TRASTUZUMAB;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; NANOTECHNOLOGY; OVARY CANCER; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 11144300731     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.08.009     Document Type: Article

References (68)

1. T.M. Allen, P.R. Cullis Drug delivery systems entering the mainstream Science 303 2004 1818 1822
2. P.C. Gokhale, B. Radhakrishnan, S.R. Husain An improved method of encapsulation of doxorubicin in liposomes Pharmacological, toxicological and therapeutic evaluation Br J Cancer 74 1996 43 48
3. G. Batist, G. Ramakrishnan, C.S. Rao Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 2001 1444 1454
4. P.S. Gill, J. Wernz, D.T. Scadden Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J Clin Oncol 14 1996 2353 2364
5. D.L. Emerson, R. Bendele, E. Brown Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211 A low-clearance liposomal formulation of lurtotecan Clin Cancer Res 6 2000 2903 2912
6. A.H. Sarris, F. Hagemeister, J. Romaguera Liposomal vincristine in relapsed non-Hodgkin's lymphomas Early results of an ongoing phase II trial Ann Oncol 11 2000 69 72
7. H. Maeda, J. Wu, T. Sawa Tumor vascular permeability and the EPR effect in macromolecular therapeutics A review J Control Release 65 2000 271 284
8. P.S. Gill, B.M. Espina, F. Muggia Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J Clin Oncol 13 1995 996 1003
9. K.A. Gelmon, A. Tolcher, A.R. Diab Phase I study of liposomal vincristine J Clin Oncol 17 1999 697 705
10. R.A. Hilger, H. Richly, M. Grubert Pharmacokinetics of encapsulated as well as free doxorubicin and its metabolites after intravenous infusion of Caelyx Proc Am Soc Clin Oncol 20 2001 116a (abstr)
11. D.W. Northfelt, L. Kaplan, J. Russell Pharmacokinetics and tumor localization of DOX-SL (Stealth liposomal doxorubicin) by comparison with Adriamycin in patients with AIDS and Kaposi's sarcoma D.D. Lasic F.J. Martin Stealth Liposomes 1995 CRC Press Boca Raton, FL 257 266
12. A. Gabizon, R. Catane, B. Uziely Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 1994 987 992
13. K.J. Harrington, S. Mohammedtaghi, P.S. Uster Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes Clin Cancer Res 7 2001 243 254
14. F.J. Martin Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin) D.D. Lasic D. Papahadjopoulos Medical Applications of Liposomes 1998 Elsevier Amsterdam 635 688
15. Z. Symon, A. Peyser, D. Tzemach Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 1999 72 78
16. F.M. Muggia, P.J. Creaven, H.H. Hansen Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880) Correlation with preclinical studies Cancer Chemother Rep 56 1972 515 521
17. R. Garcia-Carbonero, J.G. Supko Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clin Cancer Res 8 2002 641 661
18. D.F. Kehrer, A.M. Bos, J. Verweij Phase I and pharmacologic study of liposomal lurtotecan, NX 211 Urinary excretion predicts hematologic toxicity J Clin Oncol 20 2002 1222 1231
19. A.H. Calvert, R. Grimshaw, C. Poole Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA) An NCIC CTG study Proc Am Soc Clin Oncol 21 2002 208a (abstr 830)
20. F. Duffaud, M. Borner, P. Chollet Phase II study of OSI-211 (formerly NX-211, liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 22 2003 507 (abstr 2042)
21. J.H. Lee, J.M. Lee, J.K. Kim Antitumor activity of 7-[2-(N- isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor Arch Pharm Res 21 1998 581 590
22. J.H. Lee, J.M. Lee, K.H. Lim Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative Ann N Y Acad Sci 922 2000 324 325
23. J. Folkman Tumor angiogenesis Adv Cancer Res 43 1985 175 203
24. M.S. O'Reilly, L. Holmgren, Y. Shing Angiostatin A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
25. M.S. O'Reilly, T. Boehm, Y. Shing Endostatin An endogenous inhibitor of angiogenesis and tumor growth Cell 88 1997 277 285
26. L. Witte, D.J. Hicklin, Z. Zhu Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy Cancer Metastasis Rev 17 1998 155 161
27. K.S. Moulton, E. Heller, M.A. Konerding Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice Circulation 99 1999 1726 1732
28. P. Perrotte, T. Matsumoto, K. Inoue Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257 265
29. D.R. Shalinsky, J. Brekken, H. Zou Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials Ann N Y Acad Sci 878 1999 236 270
30. H.X. Chen, J.L. Marshall, E. Ness A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors Clin Cancer Res 6 2000 1259 1266
31. B. Jansen, V. Wacheck, E. Heere-Ress Chemosensitisation of malignant melanoma by BCL2 antisense therapy Lancet 356 2000 1728 1733
32. P.C. Gokhale, C. Zhang, J.T. Newsome Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome Clin Cancer Res 8 2002 3611 3621
33. A. Dritschilo, C.H. Huang, C. Fleming Infusion of liposome-encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) during radiation therapy in patients with advanced malignancies A phase I study Proc Am Soc Clin Oncol 22 2003 224 (abstr 898)
34. J. Pei, C. Zhang, P.C. Gokhale Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine Anticancer Drugs 15 2004 243 253
35. M. Shen, Y. Feng, B. Ge Liposome-C-erbB2 antisense oligodeoxynucleotides in human ovarian cancer cells Chin Med J (Engl) 114 2001 735 737
36. J.W. Park, K. Hong, D.B. Kirpotin Immunoliposomes for cancer treatment Adv Pharmacology 40 1997 399 435
37. J.W. Park, K. Hong, P. Carter Development of anti-p185HER2 immunoliposomes for cancer therapy Proc Natl Acad Sci U S A 92 1995 1327 1331
38. D. Kirpotin, J.W. Park, K. Hong Sterically stabilized anti-HER2 immunoliposomes design and targeting to human breast cancer cells in vitro Biochemistry 36 1997 66 75
39. J.W. Park, K. Hong, D.B. Kirpotin Anti-HER2 immunoliposomes Enhanced efficacy attributable to targeted delivery Clin Cancer Res 8 2002 1172 1181
40. J.W. Park, G. Colbern, K. Hong Targeted intracellular drug delivery via anti-HER2 immunoliposomes yields superior antitumor efficacy Proc Am Soc Clin Oncol 16 1997 430a (abstr)
41. J.W. Park, D. Kirpotin, R. Shalaby Anti-HER2 immunoliposomes Significantly superior efficacy vs. doxorubicin, liposomal doxorubicin, and anti-HER2 antibody treatment, via novel mechanism of action Proc Am Soc Clin Oncol 17 1998 216a
42. C. Marks, J.D. Marks Phage libraries - A new route to clinically useful antibodies N Engl J Med 335 1996 730 733
43. R. Schier, J.D. Marks, E.J. Wolf In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library Immunotechnology 1 1995 73 81
44. G.P. Adams, R. Schier, A.M. McCall Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu Br J Cancer 77 1998 1405 1412
45. M.A. Poul, B. Becerril, U.B. Nielsen Selection of tumor-specific internalizing human antibodies from phage libraries J Mol Biol 301 2000 1149 1161
46. B. Becerril, M.A. Poul, J.D. Marks Toward selection of internalizing antibodies from phage libraries Biochem Biophys Res Commun 255 1999 386 393
47. U.B. Nielsen, D.B. Kirpotin, M.A. Poul Direct selection of internalizing antibodies for immunoliposome targeting of breast tumor cells Proc Am Assoc Cancer Res 40 1999 418 (abstr)
48. U.B. Nielsen, D.B. Kirpotin, E.M. Pickering Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis Biochim Biophys Acta 1591 2002 109 118
49. T. Ishida, D.L. Iden, T.M. Allen A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs FEBS Lett 460 1999 129 133
50. D.B. Kirpotin, K. Hong, J.W. Park Anti-HER2 immunoliposomes produced by spontaneous capture of an amphipathic poly(ethylene glycol)-anti-HER2 antibody conjugate into the liposome membrane Proc Am Assoc Cancer Res 41 2000 325 (abstr)
51. D.L. Iden, T.M. Allen In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach Biochim Biophys Acta 1513 2001 207 216
52. J.W. Park, D.B. Kirpotin, K. Hong Tumor targeting using anti-her2 immunoliposomes J Control Release 74 2001 95 113
53. P.M. Ravdin Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 26 1999 117 123
54. H.B. Muss, A.D. Thor, D.A. Berry c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer N Engl J Med 330 1994 1260 1266
55. A.D. Thor, D.A. Berry, D.R. Budman erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 1998 1346 1360
56. S. Paik, J. Bryant, C. Park erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1998 1361 1370
57. M.F. Press, C. Cordon-Cardo, D.J. Slamon Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 1990 953 962
58. M.A. Cobleigh, C.L. Vogel, D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
59. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
60. K.R. Chien Myocyte survival pathways and cardiomyopathy implications for trastuzumab cardiotoxicity Semin Oncol 27 2000 9 14 discussion 92-100
61. M.S. Ewer, H.R. Gibbs, J. Swafford Cardiotoxicity in patients receiving trastuzumab (Herceptin) Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26 1999 96 101
62. J.W. Park, R. Stagg, G.D. Lewis Anti-p185HER2 monoclonal antibodies Biological properties and potential for immunotherapy R.B. Dickson M.E. Lippman Genes, Oncogenes, and Hormones Advances in Cellular and Molecular Biology of Breast Cancer 1992 Kluwer Academic Publishers Boston, MA 193 211
63. G.D. Lewis, I. Figari, B. Fendly Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunol Immunother 37 1993 255 263
64. R.M. Neve, H. Sutterluty, N. Pullen Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells Oncogene 19 2000 1647 1656
65. C.J. Langer, P. Stephenson, A. Thor Trastuzumab in the treatment of advanced non-small-cell lung cancer Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22 2004 1180 1187
66. J.W. Park, J. Smolen Monoclonal antibody therapy Adv Protein Chem 56 2001 369 421
67. J.W. Park, R.S. Kerbel, G.J. Kelloff Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development Clin Cancer Res 10 2004 3885 3896
68. C. Mamot, D.C. Drummond, U. Greiser Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res 63 2003 3154 3161